VOLUNTARY ANNOUNCEMENT: ONCOSEC RECEIVED THE CE MARK CERTIFICATION FROM EU FOR ITS GENE ELECTROTRANSFER DEVICE GENPULSE

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Grand Pharmaceutical and Healthcare Holdings Limited

遠大醫藥健康控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00512)

VOLUNTARY ANNOUNCEMENT

ONCOSEC RECEIVED THE CE MARK CERTIFICATION FROM EU FOR ITS

GENE ELECTROTRANSFER DEVICE GENPULSE™

This announcement is made by the board of directors (the "Board") of China Grand Pharmaceutical and Healthcare Holdings Limited (the "Company", together with its subsidiaries, the "Group") on a voluntary basis.

The Board is pleased to announce that OncoSec Medical Incorporated (NASDAQ: ONCS) ("OncoSec", an associate of the Group), the Group's research and development ("R&D") platform in tumor immunotherapy and DNA technology, has received the European Union's ("EU") CE mark certification for its next generation gene electrotransferdevice GenPulse™ recently. GenPulse™ is a part of the OncoSec Medical System ("OMS") electroporation device platform for the treatment of solid tumors. GenPulse™ applies short electric impulses to a tumor, causing pores to open in the membrane of cancer cells, significantly increases the uptake of anti-cancer agents into these cells. The CE mark certification marks an significant milestone in OncoSec's commercialization in Europe.

The CE mark certification is a mandatory safety certification to enter the EU market which involved a thorough evaluation and testing of the OMS electroporation device to ensure it performs safely as designed, as well as a comprehensive audit of the OncoSec's quality system. The CE mark certification from EU demonstrates that OncoSec has the capability to develop and manufacture devices that meets quality and safety requirements in the EU, and further augments the OncoSec's OMS standard in the design, development, manufacture and distribution to the International Organization for Standardization's (ISO) 13485 standard. The CE mark certification also indicates the OncoSec's electroporation device complies with standard of the European Commission (EC) and therefore can be marketed within the 31- nation European Economic Area (EEA) and Switzerland, paving the way for the subsequent commercial deployment in the U.S. and the EU.

TAVOTM, OncoSec's core product, is a global innovative cytokine-based intratumoral immunotherapy product that delivers DNA-basedinterleukin-12("IL-12") encoding in the tumor and its microenvironment. Through OMS electroporation technology, IL-12 is expressed locally in the tumor microenvironment to stimulate the immune response to react, and target and attack tumor cells, in order to inhibit the growth of the tumor cells. OncoSec has built deep and diverse clinical pipeline. Either as a monotherapy or in combination with leading checkpoint inhibitors, TAVOTM can be a potential treatment for multiple cancer

1

indications. In combination with checkpoint inhibitors enables OncoSec to address the great unmet medical need for anti-PD-1non-response in oncology. The treatment of TAVOTM in combination with KEYTRUDA® (Generic name: pembrolizumab) in anti-PD1 checkpoint resistant metastatic melanoma was granted orphan drug designation and Fast Track designation by U.S. Food and Drug Administration (FDA). The mid-stage clinical trial data from the combination treatment shows that its overall response rate (ORR) was 30%, much higher than 20% for the clinical endpoint. The Company plans to apply accelerated approval from FDA based on the data from mind-stage clinical trial to expedite the product launch. Other clinical trials of TAVOTM combined treatment of triple negative breast cancer, squamous cell carcinoma and other projects are also progressing in an orderly manner.

Sticking to patients-centered and innovation-driven, the Group will continue to expand its strategic planning in anti-tumor field and increase its investment in the world-class innovative products in the fields of radiopharmaceuticals and precision interventional therapy. Through cooperating with the three global leading anti -tumor pharmaceutical companies which are invested by the Group, including United Stated based OncoSec, Australia based Sirtex Medical Pty Limited and Telix Pharmaceuticals Limited (ASX: TLX), the Group will continue to introduce world-class innovative products for different cancer indications in response to unmet clinical needs, and enrich product pipeline and industrial strategic plan, dedicating itself into building world-leading radiopharmaceuticals platform and Immunotherapy platform. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. The Group makes full use of its domestic industrial advantages and R&D capabilities, to accelerate commercialization processes for innovative products and provide cancer patients with more advanced and diverse treatment options in the world.

Warning

The aforementioned product is still in the R&D stage. The approval of commercialization and manufacturing of such products is subject to various factors with uncertainty. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

China Grand Pharmaceutical and

Healthcare Holdings Limited

Liu Chengwei

Chairman

Hong Kong, 19 April 2021

As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Liu Chengwei, Mr. Hu Bo, Dr. Shao Yan and Dr. Niu Zhanqi and three independent non- executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.

* For identification purpose only

2